Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 9:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Determination of Death Clear all
Recruiting Phase 3 Interventional

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

NCT07173751
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Pumitamig, Nab-paclitaxel/Paclitaxel, Gemcitabine, Carboplatin, Eribulin, Matching placebo
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
58
States / cities
Springdale, Arkansas • La Jolla, California • Los Angeles, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 24, 2026, 9:11 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Rapid Reversal of CNS-Depressant Drug Effect Prior to Brain Death Determination

NCT03743805
View directory record Official record
Conditions
Brain Death, Anoxic Brain Injury, Cardiac Arrest, Sedative Intoxication, Narcotic Intoxication
Interventions
Flumazenil, Naloxone
Drug
Lead sponsor
Prisma Health-Midlands
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Jul 24, 2026, 9:11 AM EDT
Withdrawn No phase listed Observational

Study to Determine the Impact of Intraoperative Blood Pressure Management on Postoperative Outcomes (MAP-ALIVE)

NCT02019342
View directory record Official record
Conditions
Death, Postoperative Complications, Myocardial Infarction, Stroke, Renal Failure
Interventions
FACE quality improvement initiative (see below), Pre-quality improvement initiative
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Ann Arbor, Michigan • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 28, 2018 · Synced Jul 24, 2026, 9:11 AM EDT
Terminated Phase 2 Interventional Results available

Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)

NCT03407170
View directory record Official record
Conditions
Advanced Melanoma
Interventions
pembrolizumab
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Jul 24, 2026, 9:11 AM EDT
Completed Not applicable Interventional

Evaluation of Safety and Effectiveness of The SherpaPak in Donation After Circulatory Death Heart Transplantation

NCT05038943
View directory record Official record
Conditions
Heart Transplant Failure, Determination of Death, Outcomes Research, Extracorporeal Membrane Oxygenation
Interventions
Paragonix SherpaPak Cardiac Transport System
Device
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Jul 24, 2026, 9:11 AM EDT
Terminated Phase 3 Interventional

To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and Death in Diabetic Nephropathy

NCT00120328
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
SPP301
Drug
Lead sponsor
Speedel Pharma Ltd.
Industry
Eligibility
21 Years to 80 Years
Enrollment
2,364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 4, 2007 · Synced Jul 24, 2026, 9:11 AM EDT
Withdrawn Phase 2 Interventional

Trial to Determine Imaging Parameters of LMI1195 in Heart Failure Patients at Low and High Risk of Defibrillator Firing

NCT01085175
View directory record Official record
Conditions
Heart Failure
Interventions
LMI 1195
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2015 · Synced Jul 24, 2026, 9:11 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome

NCT04251026
View directory record Official record
Conditions
Mucopolysaccharidosis II
Interventions
tividenofusp alfa
Drug
Lead sponsor
Denali Therapeutics Inc.
Industry
Eligibility
Up to 18 Years · Male only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
4
States / cities
Oakland, California • Chicago, Illinois • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Jul 24, 2026, 9:11 AM EDT
Completed Not applicable Interventional

Safety and Effectiveness of NRP for DCD Heart Transplantation

NCT04626284
View directory record Official record
Conditions
Heart Transplant Failure, Determination of Death, Outcomes Research, Death
Interventions
Heart Transplantation
Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Jul 24, 2026, 9:11 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossmatch Deceased Donor Kidney Transplant

NCT01106027
View directory record Official record
Conditions
Kidney Transplant
Interventions
Eculizumab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Jul 24, 2026, 9:11 AM EDT
Completed Phase 4 Interventional Results available

Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients

NCT02781649
View directory record Official record
Conditions
End-Stage Renal Disease, Hepatitis C
Interventions
Zepatier, Ribavirin, Sofosbuvir
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Jul 24, 2026, 9:11 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)

NCT05371613
View directory record Official record
Conditions
Mucopolysaccharidosis II
Interventions
tividenofusp alfa, idursulfase
Drug
Lead sponsor
Denali Therapeutics Inc.
Industry
Eligibility
2 Years to 25 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
Oakland, California • Chicago, Illinois • Hackensack, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Jul 24, 2026, 9:11 AM EDT
Completed No phase listed Observational

Focus Groups to Determine Surrogates Views Regarding Patient Preference Predictors

NCT02898194
View directory record Official record
Conditions
Normal Physiology
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 90 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Jul 24, 2026, 9:11 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

NCT03164616
View directory record Official record
Conditions
Non Small Cell Lung Cancer NSCLC
Interventions
Durvalumab, Tremelimumab, Abraxane + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + carboplatin, Pemetrexed + cisplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
16
States / cities
Phoenix, Arizona • Bakersfield, California • Santa Monica, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jul 24, 2026, 9:11 AM EDT
Completed Phase 4 Interventional Results available

Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors

NCT03627299
View directory record Official record
Conditions
End Stage Renal Disease, Hepatitis C
Interventions
300mg glecaprevir/pibrentasivir 120mg
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Jul 24, 2026, 9:11 AM EDT
Terminated No phase listed Observational

A Study of Sleep Patterns to Determine Predictive Markers Due to Cardiovascular Disease in Elderly Patients

NCT05749263
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
13 participants
Timeline
2023 – 2024
U.S. locations
2
States / cities
Union City, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 25, 2024 · Synced Jul 24, 2026, 9:11 AM EDT
Completed Phase 4 Interventional

A Study to Determine if Antibiotics Prevent Infection in the Pancreas of Patients Where Part of the Pancreas Has Died

NCT00061438
View directory record Official record
Conditions
Pancreatitis, Acute Necrotizing
Interventions
meropenem
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
9
States / cities
San Francisco, California • Tampa, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Jul 24, 2026, 9:11 AM EDT